Relapsed/Refractory Acute Myeloid Leukemia Clinical Trials

6 recruiting

Relapsed/Refractory Acute Myeloid Leukemia Trials at a Glance

12 actively recruiting trials for relapsed/refractory acute myeloid leukemia are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 1 with 8 trials, with the heaviest enrollment activity in Houston, Beijing, and Shanghai. Lead sponsors running relapsed/refractory acute myeloid leukemia studies include Base Therapeutics (Shanghai) Co., Ltd., Chinese PLA General Hospital, and Beijing Biotech.

Browse relapsed/refractory acute myeloid leukemia trials by phase

Treatments under study

About Relapsed/Refractory Acute Myeloid Leukemia Clinical Trials

Looking for clinical trials for Relapsed/Refractory Acute Myeloid Leukemia? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Relapsed/Refractory Acute Myeloid Leukemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Relapsed/Refractory Acute Myeloid Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 1

CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid LeukemiaRelapsed/Refractory T-cell Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University25 enrolled1 locationNCT06696846
Recruiting
Phase 1Phase 2

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

T-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL+3 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 2

Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia
Chinese PLA General Hospital200 enrolled1 locationNCT06084819
Recruiting
Phase 1

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS)Relapsed/Refractory Acute Myeloid Leukemia (AML)
Cullinan Therapeutics Inc.60 enrolled11 locationsNCT05143996
Recruiting
Phase 1

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

Relapsed/Refractory Acute Myeloid Leukemia
SystImmune Inc.120 enrolled14 locationsNCT06714591
Recruiting
Phase 1

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia
Nerviano Medical Sciences124 enrolled7 locationsNCT06549790
Recruiting
Phase 1

A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Sichuan Baili Pharmaceutical Co., Ltd.130 enrolled8 locationsNCT05924750
Recruiting
Phase 1

Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Hemogenyx Pharmaceuticals LLC18 enrolled1 locationNCT06786533
Recruiting
Phase 2

Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)Relapsed/Refractory Acute Myeloid Leukemia (AML)High Risk Acute Myeloid Leukemia(AML)
Peking University People's Hospital56 enrolled1 locationNCT06869265
Recruiting
Early Phase 1

Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia
Base Therapeutics (Shanghai) Co., Ltd.9 enrolled1 locationNCT06541405
Recruiting
Early Phase 1

Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia
Base Therapeutics (Shanghai) Co., Ltd.9 enrolled1 locationNCT06541444
Recruiting
Phase 1

A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies

Relapsed/Refractory Acute Myeloid Leukemia (AML)
Nanjing Chia-tai Tianqing Pharmaceutical72 enrolled1 locationNCT06049667